Promega designs and manufactures assays, reagents and instrumentation for cellular biology, protein analysis and genomics to advance life science discovery.
ProMab Biotechnologies, Inc.
Founded in 2001., ProMab Biotechnologies develops and commercializes recombinant proteins, antibodies, and engineered immune and primary cell lines through the integration of novel technologies and decades of experience, including CAR-T/NK and mRNA-lipid nanoparticle technology. | Founded in 2001., ProMab Biotechnologies develops and commercializes recombinant proteins, antibodies, and engineered cell lines through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology, and immunology, using novel high-throughput technologies. ProMab provides its proprietary proteins, engineered cell lines, and antibodies to deliver innovative research and diagnostic products, as well as services for the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies. ProMab is also one of the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health with a focus on the field of immunotherapy, specifically CAR-T/NK cell technologies. Utilizing nearly two decades of experience generating highly specific and potent monoclonal antibodies, our success in CAR-T/NK development led us to become the first CAR-T CRO in the world. After the emergence of COVID-19, ProMab’s comprehensive experience allowed us to explore mRNA related therapies and lipid nanoparticle formulation. We now offer a fully comprehensive mRNA-LNP platform to breach new beginnings in alternative gene delivery and broadens ProMab’s offerings to many different fields of research such as vaccine research and protein replacement therapies.
PredxBio
PredxBio is a clinical decision intelligence company advancing oncology drug development through AI-driven tissue intelligence. Its proprietary SpaceIQ™ platform decodes the spatial architecture of the tumor microenvironment by integrating multiplex tissue imaging, spatial multi-omic data, and explainable AI. SpaceIQ™ converts complex spatial tissue data into reproducible, mechanistic biomarkers and decision-ready insights that guide patient stratification, clinical trial design, and program-level development decisions. By linking spatial tissue patterns to therapeutic response, PredxBio helps biopharma teams better understand mechanism of action, identify the right patient populations, and reduce late-stage clinical failure risk. PredxBio collaborates with leading pharmaceutical companies and academic cancer centers to accelerate precision oncology programs and unlock the full potential of spatial biology.
Preclina Inc
Immune Specialists’ Research Service CRO: [ Booth # 4158] Preclina is a non-clinical CRO with a fully-integrated drug discovery platform specializing in Immunology. We offer a portfolio of models for efficacy pharmacology studies in autoimmunity, immuno-oncology, and transplantation immunology. Our platforms include humanized mouse models recapitulating autoimmune diseases and humanized tumor xenografts, enabling preclinical evaluation of biologics, cell therapies, and novel immunotherapies. With over 20 years of expertise in immunology, immunotoxicology, and bioanalysis, Preclina delivers integrated, customizable solutions with a focus on scientific rigor, speed, and cost-efficiency. Our advanced approaches help accelerate drug discovery and reduce development risk. We serve as a “Bridging Specialist” connecting non-clinical and clinical stages, supporting biotech and pharma partners in optimizing pipelines and making faster, smarter decisions in immunology drug development. Meet us at Booth # 4158. Our Preclinical Services: ● Comprehensive in vivo efficacy pharmacology services utilizing well-established autoimmune and inflammatory disease models, augmented by pioneering, technically advanced humanized autoimmune disease model platforms ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and the fastest results [PreVIVO™ Platform] Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Autoimmune Specialists’ Research Service CRO: Preclina is a non-clinical CRO specialized in autoimune and inflammatory disorders, providing the utmost quality services for novel drug development at the lightning speed, highest quality, and reasonable cost. In the global market of immune disease therapeutics, which shows explosive growth, Preclina Inc is a leading company that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. [Our preclinical services] ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results (Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA) ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Preclina is a global leading non-clinical CRO that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We’re strengthening our leadership in immunological research by broadening our portfolio with sophisticated humanized mouse models, specifically optimized for oncology drug development. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. Our preclinical services: ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Immune Specialists’ Research Service CRO: [ Booth #3816] Predict Your Clinical Success with “World’s First” Humanized Models Preclina is a “Bridging Specialist” that eliminates the uncertainty of the translational gap. We provide the high-fidelity data needed to turn early-stage assets into clinical success stories. 1. Proven Excellence in Immunology – Expertise: Over 20 years specializing in immunology, immunotoxicology, and bioanalysis. – Track Record: Contributed to $600M+ global license-out deals. – Reliability: Supported multiple assets achieving final FDA approval. 2. The PreHu™ Advantage: Unrivaled Predictive Power Gain an exclusive competitive edge with our quartet of World’s First & Pioneering commercialized humanized disease models: – World’s First Lineup: Our peer-reviewed models for Psoriasis, Atopic Dermatitis, BILF, and DSS-induced Colitis are the first of their kind commercialized globally. – Peer-Reviewed Authority: All four models are published in leading journals, ensuring high reproducibility and scientific rigor. – Translational Relevance: These platforms recapitulate the human immune system in a patient-like environment to accurately validate biologics and cell therapies. 3. Operational Speed & Strategy PreVIVO™ Platform: Access modular services (PrePsora, PreBILFi, PreNASHa, etc.) for the fastest, most consistent data. – Risk Reduction: Integrated services encompass lead selection to candidate development, dramatically reducing late-stage failure rates. – Strategic Grant: The PreTrial™ Program offers exclusive grant support to qualified companies to bridge the “PoC Hurdle” and boost asset valuation. Consult with our Global Business Development team to de-risk your pipeline today [ Humanized Mouse Model Platform (PreHu™) ] 1. Humanized CDX/PDX (Patient-Derived Xenograft)-Based Efficacy Services : This platform implants tumor cells/tissues into humanized mice for bio-pharmaceutical efficacy evaluations in a patient-like environment, crucial for immuno-oncology and cell therapy assessments. – Humanized CDX/PDX Model – Humanized PBMC/HSc Model – GvHD Model 2. Humanized Autoimmune Disease / Fibrosis Mouse Model : We have pioneered the world’s first service platform with four or more humanized autoimmune disease models, providing essential preclinical services for the development of biopharmaceuticals, such as antibody drugs and cell therapies. – Humanized Ulcerative Colitis (UC) Model – Humanized Pulmonary Fibrosis (IPF) Model – Humanized Psoriasis Model – Humanized Atopic Dermatitis Model [Efficacy Evaluation Pharmacology Services (PreVIVO™) ] 1. Arthritis Research Service: Preclina’s service not only includes all essential models for evaluating the efficacy in the development of therapeutic agents for rheumatoid arthritis but also provides the key model for osteoarthritis – CIA Model / CAIA Model / ACLT Model 2. Fibrosis Research Service: With extensive expertise in immunology and fibrosis research, we have the flexibility to lead drug efficacy assessment projects with in-depth insights, maximizing the potential for success in new drug development. – BILF Model / BISF Model / MASH Model 3. Atopic Dermatitis & Psoriasis Research Service: Preclina provides specialized inflammatory skin disease models to support preclinical and mechanistic research in dermatology. These models include psoriasis, atopic dermatitis, and hypersensitivity disorders, enabling precise evaluation through mRNA analysis, protein assays, histopathology, and cellular assessments. With internationally standardized read-outs and customized research services, our models enhance the success rate of new drug development. – Imiquimod-Induced Psoriasis / IL-23-Induced Psoriasis Models – Oxazolone-Induced AD / House Dust Mite-Induced AD Models 4. Inflammatory Bowel Disease Research Service : Preclina provides specialized models for inflammatory bowel disease (IBD) research. These models include the ulcerative colitis model (Dextran Sodium Sulfate, DSS-induced colitis) and the Crohn’s disease model (Dinitrobenzene Sulfonic Acid, DNBS-induced colitis). These models accurately replicate disease onset and progression, enabling comprehensive disease activity index (DAI) assessments, histopathologic evaluations, biomarker analyses, and toxicity assessments. – DSS-Induced Colitis / DNBS-Induced Colitis Models 5. Lupus Research Service: Preclina provides key animal models for lupus and Sjogren syndrome research. For lupus, it supports the development of new drugs targeting B lymphocytes, cell surface molecules, signaling pathway proteins, and regulatory cytokines. It also offers a mouse model for Sjogren syndrome. – MRL/lpr Lupus Model / NZBW F1 Lupus Model 6. Neuroscience Research Service: Preclina provides a specialized EAE (Experimental Autoimmune Encephalomyelitis) animal model to support preclinical research and mechanistic studies on multiple sclerosis (MS). In particular, the MOG-induced EAE mouse model serves as a standard model that closely resembles the inflammatory pathogenesis of MS driven by autoimmune mechanisms, making it widely utilized for evaluating disease progression and treatment responses. – MOG EAE Model / PLP EAE Model [Non-GLP Toxicology service & ADME-PK ] Customized PK/ADME-Tox evaluation services for dramatically enhancing the potential for successful drug development.
Precision Biosystems
Precision Biosystems is Massachusetts based company that provides instrumental solution to the difficult problems of laboratory automation. Precision Biosystems is a developer and manufacturer of a BlotCycler, an automated western blot processor, based on patented fluid distribution technology. All steps after protein transfer to a membrane are fully automated: shaking, blocking, hybridization, washing, and recycling of primary antibody. BlotCycler offers unique advantages over existing technologies in using immunoblotting for research and clinical work. Unique fluidic-based washing technology allows significant increase in sensitivity and requires less antibodies. The introduction of BlotCycler made consistent, reproducible, and high quality western blot a reality. Check our website: http://precisionbiosystems.com/freetrial/
Pixelgen Technologies
Pixelgen Technologies AB is on a mission to deliver biology at the highest resolution by understanding the molecular basis of cellular function with new tools and technologies that decipher the protein interactomics of single cells in unprecedented ways. The company’s patented Proximity Network Assay delivers nanoscale spatial analysis of immune cell proteins at ultra-high capacity and underpins the Pixelgen Proxiome Kit for precision medicine. A foundational technology, the Proximity Network Assay will power a portfolio of products for translational research to accelerate advances in immunology, hematology, and cell therapy. Pixelgen was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs and is venture-backed.
Pictor Labs
Pictor Labs is redefining histopathology with the introduction of AI-powered virtual staining. Our transformational technology accelerates laboratory timelines by producing virtual stains that are indistinguishable from chemically-stained tissue, bringing improved diagnostic power to the hands of researchers and clinicians. Virtual stains provide near instantaneous results that drive discovery, improve decision-making, and increase laboratory efficiency to meet healthcare demands and maximize patient impact. Virtual staining will remove resource availability limitations, enhance control over stain consistency, and reduce specimen turnaround time, resource consumption and waste generation resulting in a greener, safer histopathology laboratory. Learn more about the science behind our technology at https://pictorlabs.ai/publications.
PamGene Int. – KinomePro
PamGene offers high-throughput kinase activity profiling, delivering critical insights into cell signaling pathways. Our technology screens multiple (cellular) kinases simultaneously, helping you understand disease mechanisms, drug effects, and resistance, and supporting translational research. Key Applications: Cancer Research: Identify new therapeutic targets and uncover resistance mechanisms to improve treatment strategies. Drug Development: Evaluate small molecule selectivity to develop more effective, targeted therapies. Biomarker Discovery: Detect kinase activity patterns that predict patient responses, enabling personalized and translational treatments. Our powerful platform also supports the development of diagnostics, including the IOpener™ diagnostic test, which predicts patient responses to immune checkpoint inhibitors like CTLA-4 and PD1. This biomarker assay approach can be applied to create other predictive diagnostics for translational research. Comprehensive Reporting: We provide detailed reports for every project, offering clear analysis, visualizations, and actionable insights, so you have all the data needed for informed decision-making. Partner with PamGene to advance your translational research and improve clinical outcomes through a deeper understanding of cellular processes.
OrgaNova
OrgaNova is a biotechnology company advancing next-generation human organoid platforms for cancer research and translational applications. We develop patient-derived and iPSC-derived organoid models using our Organoid 2.0 approach designed to better preserve native tumor architecture, cellular heterogeneity, and key microenvironmental features. OrgaNova is building a comprehensive organoid biobank and provides organoid-based CRO services, including drug screening, toxicity testing, and functional response profiling to support precision oncology and preclinical development. With operations in Philadelphia and collaborative capabilities in China, we enable scalable, high-quality organoid generation and testing to accelerate discovery and improve the predictive power of human-relevant models.
NUVISAN
Your partner of choice in bringing therapeutics to life. Nuvisan is a full-service CRO and CDMO with state-of-the-art facilities in Germany and France, supporting pharmaceutical, biotech, venture capital and non-profit partners with high-quality, end-to-end solutions that accelerate the journey from early discovery to clinical development. With more than 40 years of heritage, Nuvisan has built a reputation for scientific excellence, industry expertise and seamless integration across discovery, development and manufacturing. Our centres of excellence, including drug discovery in Berlin, provide comprehensive capabilities to advance complex programs efficiently. In oncology, Nuvisan offers a comprehensive portfolio of specialised technologies and models designed to accelerate cancer therapeutic innovation. Our capabilities encompass target validation, CRISPR/RNAi screening, custom assay development, next-generation sequencing, single-cell analyses, multiplex flow cytometry, biomarker discovery and in vivo pharmacology including PK/PD and efficacy studies. With an extensive collection of cancer models and deep translational expertise, we support programs across solid tumours, hematologic malignancies, immuno-oncology and novel therapeutic modalities. By working collaboratively to adapt to each client’s unique needs, we help de-risk development and expedite the delivery of impactful oncology therapeutics to patients worldwide. | The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient. With over 40 years of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. Recognizing the unique nature of each project, our teams prioritize flexible and innovative approaches and foster transparent communication to work closely with clients and effectively meet individual needs. | Your partner of choice in bringing therapeutics to life Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France. Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life. Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism. Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects. We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project. Discovery: Helping you to achieve key decision milestones through deep scientific insights, innovation and collaboration. Preclinical: Enabling you to successfully develop and de-risk your preclinical candidates for a smooth transition to the clinic. CMC: Collaborating with you to advance molecules into drug products. Clinical: Providing tailored clinical solutions to fully assess your drug faster. Digital: Empowering your drug discovery and development with integrated data services, machine learning and generative AI. Research phases Supporting you with integrated, tailored solutions at every step of your drug discovery and development journey.